Biomarin Pharmaceutical Inc
NASDAQ: BMRN · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-04-29
Biomarin Pharmaceutical Inc (BMRN) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for BMRN.
Valued
Fundamentals support the current valuation. Strong combination of growth, quality, and price.
BMRN historical valuation range
Where current P/E sits in BMRN's own 5Y range.
BMRN intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
BMRN valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
Current: 30.12x
P/S Ratio — History
Current: 3.25x
Is BMRN overvalued in 2026?
Biomarin Pharmaceutical Inc (BMRN) currently trades at $54.21 per share with a market capitalization of $10,477,169,000.00. Based on our multi-factor framework, the stock looks attractively valued with a Smart Value Score of 75/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
The stock trades at a P/E ratio of 30.1x, below its 5-year median of 30.5x. The PEG ratio of 0.62 suggests earnings growth is outpacing the multiple, a classic sign of undervaluation.
Looking at its own history, BMRN is currently trading cheaper than 63% of the last 5Y on P/E. This places it in the 37th percentile of its historical range, a reasonable but unremarkable position.
Our discounted cash flow model estimates BMRN's intrinsic value at $188.60 per share, against the current market price of $54.21. This implies a margin of safety of +68.02%. A meaningful cushion exists against model error, making this a reasonable risk-adjusted entry.
Financial quality is a concern. The Piotroski F-Score of 2/9 flags weakening fundamentals that deserve closer scrutiny before the valuation case can be fully trusted.
Bottom line: BMRN looks attractively valued on our framework, with a Smart Value Score of 75/100. The combination of reasonable price, healthy growth, and quality fundamentals makes it worth serious consideration.
Frequently asked questions
Is BMRN overvalued in 2026?
Based on a Smart Value Score of 75/100, BMRN is not overvalued. Fundamentals support the current price and offer reasonable margin of safety.
What is BMRN's fair value?
Our DCF model estimates BMRN's intrinsic value at $188.60 per share, versus the current price of $54.21. This produces a margin of safety of +68.02%.
What P/E ratio does BMRN trade at?
BMRN trades at a P/E of 30.1x on trailing twelve-month earnings, compared to its 5-year median of 30.5x.
Is BMRN a buy based on valuation?
WallStSmart does not issue buy or sell recommendations. Our Smart Value Score of 75/100 reflects the combined read on growth, quality, and price. The profile skews favorable for long-term accumulation.
How does BMRN's valuation compare to its history?
On P/E, BMRN currently sits in the 37th percentile of its own 5Y range. That is below its long-run median relative to where it has traded over the period.
What is BMRN's Smart Value Score?
BMRN's Smart Value Score is 75/100. The Smart Value Score is a proprietary WallStSmart metric blending growth quality, financial health, and valuation attractiveness into a single 0-100 read. Scores above 75 are rare and indicate strong multi-factor alignment.